Submitted by web@researchtop... on Fri, 05/25/2012 - 15:33
Submitted by web@researchtop... on Fri, 05/25/2012 - 15:31
Submitted by web@researchtop... on Fri, 05/25/2012 - 15:29
Submitted by web@researchtop... on Fri, 05/25/2012 - 15:27
Submitted by web@researchtop... on Fri, 05/25/2012 - 15:26
Submitted by web@researchtop... on Fri, 05/25/2012 - 15:25
Submitted by web@researchtop... on Fri, 05/25/2012 - 15:22
Submitted by web@researchtop... on Fri, 05/25/2012 - 15:21
Submitted by web@researchtop... on Fri, 05/25/2012 - 15:20
Submitted by web@researchtop... on Fri, 05/25/2012 - 15:19
Submitted by web@researchtop... on Fri, 05/25/2012 - 15:18
Submitted by web@researchtop... on Fri, 05/25/2012 - 15:15
Submitted by web@researchtop... on Fri, 05/25/2012 - 15:14
Submitted by web@researchtop... on Fri, 05/25/2012 - 14:37
Submitted by mphilemon@resea... on Fri, 05/25/2012 - 14:18
Select Publications
Bachelot T et al. TAMRAD: A GINECO randomized Phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). San Antonio Breast Cancer Symposium 2010;Abstract S1-6.